Fritz G. Buchanan

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Loren Lasko, Clarissa G. Jakob, Rohinton Edalji et al. · Nature · 2017 · 858 citations · Full text

Medicine, Cancer Biology, Oncology +8

ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope

Andrew C. Phillips, Erwin R. Boghaert, Kedar S. Vaidya et al. · Molecular Cancer Therapeutics · 2016 · 184 citations · Full text

Medicine, Oncology, Pharmacology +15

The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia

William N. Pappano, Jun Guo, Yupeng He et al. · PLoS ONE · 2015 · 94 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody

Edward B. Reilly, Andrew C. Phillips, Fritz G. Buchanan et al. · Molecular Cancer Therapeutics · 2015 · 82 citations

Medicine, Oncology, Pharmacology +17

Optimization of Phenyl-Substituted Benzimidazole Carboxamide Poly(ADP-Ribose) Polymerase Inhibitors: Identification of (<i>S</i>)-2-(2-Fluoro-4-(pyrrolidin-2-yl)phenyl)-1<i>H</i>-benzimidazole-4-carboxamide (A-966492), a Highly Potent and Efficacious Inhibitor

Gui‐Dong Zhu, Jianchun Gong, Sheela A. Thomas et al. · Journal of Medicinal Chemistry · 2010 · 71 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15